Mon, Sep 22, 2014, 7:14 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

SIGA Technologies, Inc. Message Board

beavertail_splash 4674 posts  |  Last Activity: 5 hours ago Member since: Apr 13, 2007
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    GERN, ASTY, INCY SP & Techy talk

    by beavertail_splash Aug 22, 2014 11:37 PM
    beavertail_splash beavertail_splash 5 hours ago Flag

    the downward trend line again resumed was revised upwards a notch about two weeks ago when things looked bullish. Bought more time till the $2.00 Sept. target.
    We all saw what happened to ASTY since August 22
    INCY; $47.3 is trading in a rising wedge pattern

  • beavertail_splash by beavertail_splash 6 hours ago Flag

    made it's bookies $300B in commish and took the wind out of the US markets. His band of thieves included
    Citigroup Inc, Credit Suisse Group AG, Deutsche Bank, Goldman Sachs Group Inc being the main stabilizing agent, JPMorgan Chase & Co and Morgan Stanley acted as joint book runners of the IPO.
    Sounds more like a racketeering scam to me.

  • Reply to

    What Happened? High Volume

    by ryan_weisman2011 Sep 20, 2014 2:24 PM
    beavertail_splash beavertail_splash 19 hours ago Flag

    the SP moved 1 cent on 1mil shares being exchanged at end of day. This was likely options covering. Earlier the trades where balanced btwn sells and buys price being dropped during slow vol. Clearly a gaming program in play. Someone wants shares without driving SP up.

  • Reply to

    200k block of shares dumped

    by hairypotter9 Sep 18, 2014 3:08 PM
    beavertail_splash beavertail_splash Sep 21, 2014 1:34 AM Flag

    a dump is sometimes used later as a tasty Castor fiber filled treat. Coprophagous critters (beavers) like hedge funds do it all the time. Did you notice the mil share vol transaction 1 minute prior to close? BURP ;=3D

  • beavertail_splash beavertail_splash Sep 21, 2014 1:21 AM Flag

    the Yale study on synergistic tumor suppression by combined inhibition of `telomerase and CDKNIA overview by Michael Green, June 19, 2014 (sent for review June 8, 2014) stated
    "In fact, the telomerase inhibitor imetelstat, a oligonucleotide that inhibits telomerase activity by binding to the RNA component of human telomerase RNA (hTR), has advanced to the clinic for treatment of various hematological malignancies and solid tumors. To date, however, telomerase-based monotherapies have not been successful, underscoring the need to understand in greater detail how cancer cells respond to telomerase inhibition."
    Too bad the MAYO MF clinical partial hold wasn't lifted till June 12, 2014 by the FDA after this was submitted for review, otherwise Michael would have qualified by stating "To date, although telomerase-based monotherapies have not yet been successful, imetelstat is showing promising results in MF, MDS, AML, and Blast Phase MF clinical trials."

  • Reply to

    Telomerase is red hot in the scientific news

    by clempsonman Sep 20, 2014 2:25 PM
    beavertail_splash beavertail_splash Sep 20, 2014 11:17 PM Flag

    To quote the GERN company website "Imetelstat is covered by multiple patent families including those relating to our proprietary nucleic acid chemistry and telomerase technologies. We developed imetelstat from inception and own exclusive worldwide commercial rights with U.S. patent coverage extending through 2025." The others are just simply water skeeter chasers. GERN owns the real thing.

  • beavertail_splash beavertail_splash Sep 20, 2014 3:19 AM Flag

    END it looks like those bears hauled in a whooper net full at the end of the day.
    348,000 shares @3:59pm and a minute later 771,000 shares @4:00pm.
    Volume for the day spiked as a result to 4,186,000 shares. We have news coming, we have almost 1 mil shares end of day buying. Things are adding up. All that's missing is SP increase.
    Anyone else have any ideas as to the EOD volume spike?

  • beavertail_splash beavertail_splash Sep 19, 2014 10:58 PM Flag

    Intermune sounds alot like Gern; " never turned a profit in 16 years of existence and other than its clinical expertise the company holds a single asset: an idea for treating a lethal blood disorder with no known cause or cure" Myelofibrosis occurs when blood stem cells develop a genetic mutation. It's not clear what causes the genetic mutation in blood stem cells. The end result is usually a lack of red blood cells — which causes the anemia characteristic of myelofibrosis — and an overabundance of white blood cells with varying levels of platelets. In people with myelofibrosis, the normally spongy bone marrow becomes scarred.
    Gern's promising drug Imetelstat has shown to effectively reverse this abnormality and offer several patients Complete Remissions treated with it. The FDA's clinical hold on Imetelstat has denied thousands of dying people with MF better and possibly longer lives with the little time they have left.
    The only FDA drug approved for treatment is ruxolitinib (Jakafi). It's still not yet clear whether these medications can help people with myelofibrosis live any longer. Ruxolitinib works by stopping the action of all JAK-related genes in the body, including those found in both healthy and diseased cells. Because healthy cells are affected, side effects such as bleeding, infection, bruising, dizziness and headaches may occur.

  • beavertail_splash beavertail_splash Sep 19, 2014 3:24 PM Flag

    could use a bone to gnaw on about now. All this wood fiber and willow bark is making me bloat.

  • beavertail_splash beavertail_splash Sep 19, 2014 1:53 PM Flag

    Not sure if you could call this a sell off. There was some questionable vol trades around 11:30 am an 87k block bought and then sold. A number of larger blocks started selling at noon...55k,41k,46k,144k,56k triggering a 10 cent SP drop & subsequent buying increase in smaller blocks...52k.29k,28k,19k,11k looks like SP gaming to me as small lot buys resumed @1:30pm 11k,17k, 30k,15k,31k,33k creating a zero sum game.
    Options plays(which I don't play) are at work with triple witching covering on the market today set to expire for Sept 20th close date.

  • Reply to

    200k block of shares dumped

    by hairypotter9 Sep 18, 2014 3:08 PM
    beavertail_splash beavertail_splash Sep 18, 2014 3:20 PM Flag

    well when it only achieved a 2 cent drop in SP it wasn't too bright now was it? At low vol. any such moves would have had a much bigger impact on SP if it wasn't being gamed like GERN. There was someone who bought the entire block 2 cents below the offer. It's called hedge fund ping pong.

  • beavertail_splash beavertail_splash Sep 18, 2014 3:03 PM Flag

    BM unless you forgot there were dozens of law suits launched against the company following the clinical hold news. Doubt any had merit but the damage on SP was significant when you consider it would only take some unscrupulous lobby interest to pay out the $50 fee required to register each of the dozens of suits. Never saw a class action with so many separate firms filing individually. For a measly couple of grand of incurred costs you could wipe out 10's of millions in company public market capital and silence the CEO during the course of these actions. Add to this the FDA's clinical hold coming from left field based on very weak and inconsistent data concerns stemming from completely different trials showing unprecedented efficacy in both ET and MF ranging over a three year period(ET trials). It makes no cents. At least for shareholders.
    Black you bring up valid points but the way you keep ENDLESSLY going on about Chippy and bad management me thinks someone like yourself could easily be behind such efforts. No one knows who really did what but the space is riddled with questions and concerns. Repeating that management is the culprit is only half the story. There are many other possibilities. With so much to gain GERN has attracted competitors like INCY with so much to lose. I'm sure they won't take this lying down. To delay GERN they just extend their profitable market niche offering little efficacy (treats only symptoms of the disease) & high risks wrt toxicity to
    patients with myeloproliferative disorders. Imet on the other hand has shown results in remissions that make it "tantamount to a cure". Interesting to note the latest (newest) brochure from MAYO doesn't even mention INCY's Ruxolitnib as a treatment for MF under their hematological cancer heading. Remissions trump comfort at the MAYO and are supported by latest trial data wrt to ET & MF studies.

  • beavertail_splash beavertail_splash Sep 18, 2014 12:17 AM Flag

    In reference to the cessation of the MF First study, Scarlett said the “decision had nothing to do with liver test abnormalities. That was never discussed and we are unaware of any reason vis-à-vis liver abnormalities that played any role in stopping that study.” - See more at: FDA-Asks-Geron-to-Halt-Imetelstat-Development. Apparently Chippy begs to differ.
    Imetelstat initially garnered attention at the 2012 ASH annual meeting when phase II results were presented for patients with refractory essential thrombocythemia (ET). In the study, patients were treated with weekly intravenous imetelstat. Updated findings from 18 patients with ET were presented in June 2013 at the European Hematology Association (EHA) Congress. At this point, imetelstat elicited a complete response rate of 89% following a median 14-month duration of treatment.
    “We were surprised by these actions,” John “Chip” Scarlett, MD, the president, CEO, and director at Geron, said regarding the verbal notice of the full clinical hold during a webcast conducted following the announcement on March 12.
    “An expert panel of liver experts along with our internal safety staff have periodically reviewed the data and all possible liver-related SAEs [serious adverse events],” Scarlett said. “Our and their conclusions were that the benefit-risk profile of imetelstat was favorable. These conclusions remained consistent as the ET trial progressed.” The FDA slapped this clinical hold a year and a half after the initial ET study results were presented at ASH 2012 and updated last year at ASH 2013. Tell me the FDA knows what they are doing by their actions?

  • beavertail_splash by beavertail_splash Sep 17, 2014 12:46 PM Flag

    The results of a Mayo Clinic study demonstrate that
    a drug named imetelstat induces remissions in some
    patients with myelofibrosis. This is a form of chronic
    leukemia that affects the patient’s bone marrow
    that is replaced by fibrosis (scar tissue) instead
    of blood-producing cells.
    Scientists do not yet know the exact mechanism of
    action for imetelstat, but believe it interferes with the
    survival and proliferation of cancer cells by inhibiting
    a critical enzyme called telomerase. One of the functions
    of telomerase is to repair the ends of chromosomes
    called telomeres, and because cancer cells have shorter
    than normal telomere size, they are particularly susceptible
    to the drug.
    The study results are promising. Some patients
    participating in the clinical trial taking imetelstat obtained
    dramatic responses, and we have seen some complete
    responses (tantamount to a cure), which is almost
    unheard of in this disease.
    New Drug Induces Remissions in Myelofibrosis
    Although patients may experience relief in response
    to other treatments, their bone marrow does not
    usually return to normal. But in the case of this new
    therapy, some of the patients participating in the trial
    developed normal bone marrow.
    Researchers studied imetelstat in 33 patients at
    Mayo Clinic and have now followed the first 22 patients
    for more than six months. Among these 22 patients,
    two achieved complete remissions and three partial
    remission, including reversal of bone marrow fibrosis
    in four of the five patients

  • beavertail_splash beavertail_splash Sep 17, 2014 12:38 PM Flag

    some hedge fund backed with deep pockets no doubt standing behind naked with shorts off. Almost thought it was Maine.

  • Reply to

    SEC failure

    by carolyn.whitney26 Sep 16, 2014 10:13 PM
    beavertail_splash beavertail_splash Sep 17, 2014 12:33 PM Flag current hedge fund owners don't blatantly lie to investigators and what happens to them? She was made an example of, 5 months for fibbing. She claimed she had not been aware of any impropriety at the time. Maybe she actually thought that. Her broker was not prosecuted. He should have known better.

  • beavertail_splash beavertail_splash Sep 17, 2014 12:16 PM Flag

    The FDA is obviously complicit with the INCY lobby in delaying GERN's progress on MF trials. As per MAYO CLINIC; "The study results are promising. Some patients
    participating in the clinical trial taking imetelstat obtained
    dramatic responses, and we have seen some complete
    responses (tantamount to a cure), which is almost
    unheard of in this disease."
    Irish husbands remission count has been 18 months now and has shown bone marrow healing of scar tissue in his "cured" response. How can they possibly delay this and for what? Jakafi, a toxic oncology 'placebo' has been a failure. JMHeart felt Observatons

  • Reply to

    SEC failure

    by carolyn.whitney26 Sep 16, 2014 10:13 PM
    beavertail_splash beavertail_splash Sep 17, 2014 10:15 AM Flag

    It's an old boys network...she's a girl.

  • Reply to

    PIP is plainly now worth more than $4.11 / share

    by teebrane Sep 16, 2014 1:28 PM
    beavertail_splash beavertail_splash Sep 17, 2014 1:19 AM Flag

    this from SIGA's PR
    "The commencement of the chapter 11 case will prevent PharmAthene from taking any enforcement action at this time and also will permit SIGA's intended appeal to go forward.
    Dr. Eric A. Rose, SIGA's Chairman and Chief Executive Officer, said, "Enforcement of the expected judgment of the Court of Chancery would threaten SIGA's viability, its ability to produce and deliver our smallpox drug, Tecovirimat, and its critical role in Project BioShield. We remain committed to performing under SIGA's contract with BARDA, obtaining FDA approval for Tecovirimat, and growing our company. SIGA has adequate liquidity to conduct its operations, satisfy all of its contractual commitments, and, with the stay afforded by chapter 11, pursue its appellate rights."
    Doesn't look like something that will be resolved anytime soon. What will PIP ride on in the meantime?

  • beavertail_splash beavertail_splash Sep 17, 2014 12:47 AM Flag

    Honestly if the FDA did make a human error on this hold, I'm sure 6 months would be adequate time to reverse their decision. We haven't seen anything indicating such safety trial issues to warrant such action.

1.34+0.05(+3.88%)Sep 22 3:59 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.